Trent Kamke Sells 2,928 Shares of LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider Trent Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider owned 3,749 shares in the company, valued at $401,143. This represents a 43.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $97.22 on Wednesday. LeMaitre Vascular, Inc. has a 1-year low of $78.35 and a 1-year high of $118.01. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of 35.87, a P/E/G ratio of 2.82 and a beta of 0.60. The stock’s fifty day simple moving average is $109.87 and its 200-day simple moving average is $94.76.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The business had revenue of $66.55 million for the quarter, compared to the consensus estimate of $66.67 million. During the same quarter in the previous year, the company posted $0.48 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, sell-side analysts predict that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st will be paid a $0.25 dividend. The ex-dividend date is Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 1.0%. LeMaitre Vascular’s payout ratio is 36.90%.

Wall Street Analyst Weigh In

LMAT has been the topic of a number of recent research reports. Roth Mkm restated a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Citizens Jmp boosted their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Wells Fargo & Company boosted their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and a consensus target price of $112.60.

Institutional Trading of LeMaitre Vascular

Large investors have recently made changes to their positions in the stock. Sound Income Strategies LLC boosted its stake in shares of LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 183 shares in the last quarter. Cornerstone Planning Group LLC boosted its stake in shares of LeMaitre Vascular by 534.0% during the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 283 shares in the last quarter. Catalyst Capital Advisors LLC bought a new stake in shares of LeMaitre Vascular during the 1st quarter worth about $32,000. MAI Capital Management bought a new stake in shares of LeMaitre Vascular during the 3rd quarter worth about $38,000. Finally, First Horizon Corp bought a new stake in shares of LeMaitre Vascular during the 3rd quarter worth about $39,000. Institutional investors own 84.64% of the company’s stock.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Negative Sentiment: CEO George W. Lemaitre sold two blocks of stock last week, including 27,881 shares and 18,600 shares, which can weigh on investor sentiment because executives selling shares often raises concerns about near-term upside. Article: LeMaitre Vascular CEO George Lemaitre Sells 27,881 Shares Article: LeMaitre Vascular CEO George Lemaitre Sells 18,600 Shares of Stock
• Negative Sentiment: Director Bridget A. Ross and insider Trent G. Kamke also sold shares, adding to the impression that management is trimming exposure across multiple levels of the company. Article: LeMaitre Vascular Director Bridget Ross Sells 5,044 Shares of Stock Article: LeMaitre Vascular Insider Trent Kamke Sells 2,928 Shares
• Neutral Sentiment: Short interest data showed essentially no short positions, so short-selling does not appear to be a meaningful driver of the stock move. Article: LeMaitre Vascular Insider Trent Kamke Sells 2,928 Shares
• Positive Sentiment: Recent earnings were stronger than expected, with Q1 EPS of $0.68 beating estimates and revenue rising 11.1% year over year, and management also raised FY2026 guidance; these fundamentals help support the longer-term outlook. LeMaitre Vascular stock report

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.